Wall Street's rough month, Powell's inflation outlook, GLP-1 subscription and more in Morning Squawk

WTI May futures settled above $100 and Brent futures are up roughly 55% month-to-date while U.S. average gas hit $4/gal for the first time since 2022; major indexes are on track for their worst monthly and quarterly losses since 2022 and the CBOE VIX has risen >50% in March (more than doubled in 2026). Fed Chair Powell said the inflation outlook is stable and that current rates are "a good place," and traders sharply lowered rate-hike odds after his remarks. Corporate/sector notes: Opendoor is acquiring Doma's closing and escrow businesses, Novo Nordisk launched multi-month Wegovy subscriptions to compete with Eli Lilly, and JetBlue raised checked-bag fees by at least $4 amid higher fuel costs.

Analysis

The primary market lever here is an oil-price shock that transmits through consumer budgets and corporate margins unevenly: energy producers and refinery chains get near-term free cash flow upside while high-fixed-cost consumer services (airlines, travel, discretionary retail) face margin compression and demand elasticity within a 1–3 month window. Mortgage-sensitive businesses and fintechs in the real-estate stack see immediate flow reduction — that increases the value of any cash-generating, vertically integrated closing/escrow business because it supplies short-term float and lowers per-transaction funding costs by an estimated few hundred dollars per home once fully integrated.

Monetary policy is the wild card for asset re-pricing. If central banks accept transient energy-driven inflation and stay on hold, risk assets will stabilise within 1–3 months; if wage or inflation expectations re-accelerate, the tightening path resumes and rotates winners back to real assets and short-duration cash businesses. Geopolitical outcomes are asymmetric: a swift de-escalation collapses energy risk premia quickly (weeks) and penalises leveraged energy bets, whereas protracted disruption (months) magnifies structural shifts — higher capex for onshore U.S. production and faster expense pass-through in staples and services.

On healthcare, the subscription play compresses headline ARPU but increases retention and lifetime value; that is good for cash flow predictability but bad for near-term revenue comps versus a market rewarding topline acceleration. The consensus underprices the optionality of operational float from escrow/closing units and overprices the durability of premium pricing for GLP-1s once oral competitors scale — both are 6–18 month stories with sizeable asymmetric outcomes.

Key Decisions for Investors

• Pair trade (3-month): Long XLE ETF (or overweight 2–4 mid-cap E&Ps with strong balance sheets like PXD/DVN) and short JETS ETF (or underweight JBLU). R/R: target 20–35% relative upside if energy stays elevated; stop if Brent-equivalent drops >15% in 10 trading days (cuts potential loss to ~25%).
• Opendoor (OPEN) tactical (6–12 months): Buy OPEN stock or buy a buy-write/LEAP call (limit to 1.5–2% portfolio). Thesis: capture margin improvement from closing/escrow float; R/R: aim for 40–80% upside if integration reduces per-transaction cost by $200–400; downside capped by housing-cycle risk — set hard stop at 30% drawdown.
• GLP-1 pair (6–12 months): Long Eli Lilly (LLY) and short Novo Nordisk (NVO) equal notional or buy NVO 6–12 month put spread vs LLY calls. R/R: expect 15–40% relative win for LLY if oral GLP-1 adoption accelerates and pricing competition compresses NVO ASPs; risk is sector-wide expansion that lifts both (limit exposure to 1–2% portfolio).
• Macro tail hedge (1–6 months): Small position (0.5–1% portfolio) in GLD calls or physical GLD to protect vs sticky inflation/geopolitics. R/R: asymmetric payoff if energy-driven CPI stickiness returns; cost is small premium/drag if volatility subsides.